Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Phase 2 Completed
454 enrolled 23 charts
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Phase 3 Completed
305 enrolled 10 charts
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Phase 2 Completed
58 enrolled 16 charts
Sorafenib in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
23 enrolled
Vaccine Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Phase 2 Completed
30 enrolled 15 charts
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Phase 1/2 Completed
60 enrolled 6 charts
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Phase 1/2 Completed
48 enrolled 14 charts
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Phase 1 Completed
40 enrolled
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Phase 1 Completed
45 enrolled
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
Phase 2 Completed
19 enrolled 6 charts
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Phase 1 Completed
13 enrolled
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
Phase 2 Completed
26 enrolled 9 charts
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
Phase 1/2 Completed
54 enrolled 9 charts
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
22 enrolled
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Phase 1/2 Completed
53 enrolled
Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer
Phase 1 Completed
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
20 enrolled
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
24 enrolled 4 charts
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Phase 1 Completed
28 enrolled
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
Phase 1/2 Completed
16 enrolled 7 charts
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
Phase 2 Completed
61 enrolled 12 charts
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
Phase 2 Completed
226 enrolled 8 charts
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
12 enrolled 8 charts
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Phase 1 Completed
68 enrolled
Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer
Phase 2 Completed
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
37 enrolled
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
Phase 1 Completed
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
Phase 2 Completed
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 2 Completed
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase NA Completed
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 2 Completed
Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 1/2 Completed
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
Phase 2 Completed
37 enrolled
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase 1 Completed
18 enrolled
Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
Phase 2 Completed
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer
Phase 1 Completed
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Irofulven in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
32 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
Decitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
24 enrolled
Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
Phase 2 Completed
42 enrolled
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
48 enrolled
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
132 enrolled
FR901228 in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
37 enrolled
Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
35 enrolled
Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
Phase 2 Completed
56 enrolled